✦ LIBER ✦

Survival analyses from the ZEBRA study: goserelin (Zoladex™) versus CMF in premenopausal women with node-positive breast cancer

✍ Scribed by M. Kaufmann; W. Jonat; R. Blamey; J. Cuzick; M. Namer; I. Fogelman; J.C. de Haes; M. Schumacher; W. Sauerbrei

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Updated survival analyses from the ZEBRA

✍ M. Schumacher; R. Blamey; J. Cuzick; J. De Haes; W. Eirmann; I. Fogelman; W. Jon 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 201 KB

The ZEBRA study: Zoladex™ is as effectiv

✍ R. Blamey 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 257 KB

O-3 Long-term results from the ZEBRA tri

✍ M. Kaufmann; W. Jonat; W. Sauerbrei; R. Blamey; M. Schumacher; for the Zoladex E 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 162 KB

P107 The ‘ZEBRA’ study: ‘Zoladex’ (goser

✍ W. Jonat; M. Kaufmann; R. Blamey; T. Sheldon 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 156 KB

The ZEBRA study: Early benefits in quali

✍ M. Olschewski; H. de Haes 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 128 KB

Bone mineral density in premenopausal wo

✍ I. Fogelman; G.M. Blake; R. Blamey; M. Palmer; W. Sauerbrei; M. Schumacher; D. S 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 232 KB